Home' Australian Pharmacist : Australian Pharmacist January 2014 Contents Australian Pharmacist January 2014 I ©Pharmaceutical Society of Australia Ltd.
There is a need for greater awareness
among health professionals, including
pharmacists, of this adverse drug
reaction.15 Assessing for drug-induced
taste disorders should form part of any
comprehensive geriatric assessment
or medication review, especially in
elderly people in residential aged care
facilities, with conditions that require
multiple medications, as well as in elderly
patients who are malnourished or at risk
The most useful drugs for treating chronic
diseases typical of the elderly are also
a potential cause of taste disorders, so
periodically reviewing pharmacological
therapies is not just a matter of good
clinical practice, but also helps to prevent
or contain taste disorders.1
1. Imoscopi A, Inelmen EM, Sergi G, Miotto F, Manzato
E. Taste loss in the elderly: epidemiology, causes and
consequences. Aging Clin Exp Res. 2012;24(6):570--9.
2. Arcavi L, Shahar A. Drug related taste disturbances:
emphasis on the elderly. Harefuah. 2003;142(6):446--50,
3. McNeil JJ, Anderson A, Christophidis N, Jarrott B, Louis WJ.
Taste loss associated with captopril treatment. Br Med J.
4. Heeringa M, van Puijenbroek EP. Reversible dysgeusia
attributed to losartan. Ann Intern Med. 1998;129(1):72.
5. Sadasivam B, Jhaj R. Dysgeusia with amlodipine - a case
report. Br J Clin Pharmacol. 2007;63(2):253.
6. Cave AJ, Cox DW, Vicaruddin O. Loss of taste with
clopidogrel. Can Fam Physician 2008;54(2):195--6.
7. Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB,
Ohrn KE, Elting LS, et al. A systematic review of dysgeusia
induced by cancer therapies. Support Care Cancer.
8. Ackerman BH, Kasbekar N. Disturbances of taste and smell
induced by drugs. Pharmacother. 1997;17(3):482--96.
9. Anon. Drug-induced taste disorders. Prescrire Intern.
10. Tomita H, Yoshikawa T. Drug-related taste disturbances.
Acta oto-laryng Suppl. 2002(546):116--21.
11. Nin T, Umemoto M, Miuchi S, Negoro A, Sakagami M.
Treatment outcome in patients with taste disturbance.
Nihon Jibiinkoka Gakkai kaiho. 2006;109(5):440--6.
12. Doty RL, Shah M, Bromley SM. Drug-induced taste
disorders. Drug Safety. 2008;31(3):199--215.
13. Shinkai RS, Hatch JP, Schmidt CB, Sartori EA. Exposure to
the oral side effects of medication in a community-based
sample. Spec Care Dentist. 2006;26(3):116--20.
14. Anon. A better understanding of drug-induced taste
disturbances may improve management of the condition.
Drugs Ther Perspect. 2008;24(12):22--24.
15. Naik BS, Shetty N, Maben EV. Drug-induced taste disorders.
Eur J Int Med. 2010;21(3):240--3.
16. Meyer D, Hartmann K, Kuhn M. Drug-induced taste
disorders. Praxis. 1996;85(46):1468--72.
17. Ratrema M, Guy C, Nelva A, Benedetti C, Beyens MN,
Grasset L, et al. Drug-induced taste disorders: analysis of
the French Pharmacovigilance Database and literature
review. Therapie. 2001;56(1):41--50.
18. Griffin JP. Drug-induced disorders of taste. Adverse Drug
React Tox Rev. 1992;11(4):229--39.
19. Doty RL, Bromley SM. Effects of drugs on olfaction and
taste. Otolaryngol Clin N Am. 2004;37(6):1229--54.
20. Schwartz H, Krause R, Siepman N, Haber M, Weissfeld A,
Kidd S, et al. Seven-day triple therapy with lansoprazole,
clarithromycin, and metronidazole for the cure of
Helicobacter pylori infection: a short report. Helicobacter.
21. Mansour-Ghanaei F, Shafaghi A, Fallah M. The effect of
metronidazole in treating human fascioliasis. Med Sci
22. Doty RL, Philip S, Reddy K, Kerr KL. Influences of
antihypertensive and antihyperlipidemic drugs on
the senses of taste and smell: a review. J Hypertens.
OTC switching a priority
Prescription to non-prescription
reclassification ('Rx to OTC switch')
and lifting the current advertising
restrictions on S3 communication
remain high on the Australian Self
Medication Industry's (ASMI) agenda.
According to ASMI Executive
Director Dr Schoombie, the inability
of companies to create consumer
awareness of S3 medicines is the main
reason why the full potential of these
medicines as a legitimate treatment
option has not been realised in Australia.
Speaking at the ASMI Conference
recently, Dr Schoombie said it was
difficult to a mount a public health
benefit argument to support these
restrictions, especially given the
supply of these medicines requires
the mandatory intervention by
'The restrictions have a perverse
consequence; consumers who do not
know about these medicines continue
to go to their GPs for conditions that
could have been effectively and safely
treated by pharmacists.'
ASMI has been working with
stakeholders, including pharmacy and
consumer groups, on an alternative
consumer communications model which
will permit branded communication of
certain S3 products. It is now exploring
options for reform with Federal, State
and Territory health authorities.
Under the proposed model, the
emphasis will be on creating consumer
awareness about the condition
and/or symptoms for which the
particular S3 product is indicated, and
highlighting the importance of the
role of the pharmacist in determining
whether the product is appropriate for
ASMI recently included the proposed
S3 Communications model as part of
its response to the consultation on the
review of the scheduling framework
as well as the recent consultation into
advertising of therapeutic goods.
Dr Schoombie said, 'In ASMI's view,
increasing the number of S3 products
will have a myriad of benefits across
the community such as health funding
savings, reduced pressure on doctors,
more timely access to medicines
for consumers and an increased
ability for consumers to self-care for
'For pharmacists, an increase in products
down-scheduled to S3 from prescription
status will provide them with more
effective tools to treat their customers
and an opportunity to build new,
diversified business models. But for this
level of change to happen, companies
need to be incentivised to invest in
down-scheduling products to S3.
Dr Schoombie said that innovator
companies are presently disadvantaged
by the OTC down-scheduling process,
due to the lack of data protection
for 'switch' applications. ASMI is
advocating for a period of data
protection, commensurate with the
degree of innovation and investment,
to encourage investment in Rx to
Links Archive Australian Pharmacist December 2013 Australian Pharmacist February 2014 Navigation Previous Page Next Page